The formulation is being developed in collaboration with United Therapeutics Corporation United Therapeutics made an additional $5 million ...

A major catalyst window opens for this biopharma stock with Q1 earnings due on May 6, and two key FDA decisions in May and ...

MannKind Corporation (NASDAQ:MNKD) is one of the 10 Best Penny Stocks to Buy Before They Explode. On May 7, 2026, Wells Fargo ...

Q1 2026 Management view "In the first quarter, we continued to execute our strategy to evolve MannKind to a diversified company positioned to deliver sustained long-term growth," said CEO Michael ...

View MannKind Corporation MNKD stock quote prices, financial information, real-time forecasts, and company news from CNN.

MannKind (NASDAQ: MNKD) was a stock to avoid on the second-to-last trading day of the week. Investors eagerly sold out of the commercial-stage biotech's equity, as they clearly felt its latest ...

MannKind's shares soared after the company revealed it has been developing a dry powder inhalation formulation of ralinepag over the past six months for United Therapeutics. Shares of MannKind climbed ...

CEO Michael Castagna sold 65,804 shares on Dec. 17, 2025, for a total value of approximately ~$395,482 at a weighted average price around $6.01 per share. This transaction represented 2.56% of Mr.

Q1 2026 total revenues of $90.2M, +15% vs. Q1 2025Built out launch infrastructure and aligned field-based teams for upcoming ...

The company will host a webcast beginning at 4:30 p.m. Eastern Time to review the financial results and provide a business update.

There's nothing like an estimate-topping quarter to put some pep in a company. A big jump in royalty revenue was particularly notable. The reason for the stock's jump wasn't hard to tease out.